Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(26 sites)
United States
City of Hope Comprehensive Cancer Center, Duarte, California UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California UCHealth University of Colorado Hospital, Aurora, Colorado Northwestern University, Chicago, Illinois Memorial Hospital East, Shiloh, Illinois University of Kentucky/Markey Cancer Center, Lexington, Kentucky Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland National Institutes of Health Clinical Center, Bethesda, Maryland Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri Washington University School of Medicine, St Louis, Missouri Siteman Cancer Center-South County, St Louis, Missouri Siteman Cancer Center at Christian Hospital, St Louis, Missouri NYU Langone Hospital - Long Island, Mineola, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio Ohio State University Comprehensive Cancer Center, Columbus, Ohio University of Cincinnati Cancer Center-West Chester, West Chester, Ohio University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin